Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Aberrant expression of HLA-DR antigen by bone marrow-derived mesenchymal stromal cells from patients affected by acute lymphoproliferative disorders

Leukemia volume 21, pages 378–381 (2007)Cite this article

Mesenchymal stromal cells (MSCs) can be isolated from various sources and their plasticity and multilineage potential to differentiate into other mesodermal cells has been widely reported.1, 2 Host immune response has been the subject of numerous recent studies, in which it was demonstrated that MSCs have an immunomodulant role.3 Human MSCs have been shown to escape recognition by alloreactive T cells in mixed lymphocyte reaction cultures (MLR).3 The evidence that in vitro culture-expanded MSCs can be infused intravenously without toxicity have suggested that allogeneic MSC have many advantages in therapeutic applications such as enhancement of hematopoietic stem cells engraftment and reduction of the incidence and severity of graft-versus-host disease.4 The immunosuppressive nature of differentiated and undifferentiated bone-marrow (BM)-MSCs could also be of clinical importance in the treatment of autoimmune diseases.4 However, the mechanisms by which MSCs can exert their immunomodulant role are under investigation.5 Moreover, a few data are available in the literature regarding the heterogeneous pattern of response in inhibiting T-cell proliferation by cultured BM-MSCs from patients with hematological malignancies.6

In this study, the expression of human leukocyte antigen (HLA), major histocompatibility complex (MHC) class I and II were investigated on in vitro cultured BM-derived MSCs, based on the notion that either undifferentiated or differentiated MSCs express intermediate levels of HLA class I, but do not express the class II molecules.7 However, it is known that HLA-DR expression by MSCs can be induced by stimulation with interferon γ. Interestingly, both undifferentiated and differentiated MSCs do not express costimulatory molecules such as B7-1, B7-2, CD40 or CD40L and fail to elicit proliferation of allogeneic lymphocytes.7

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Horwitz EM, Le Blanc K, Dominici M, Mueller I, Slaper-Cortenbach I, Marini FC et al. Clarification of the nomenclature of MSC: The International Society for Cellular Therapy position statement. Cytotherapy 2005; 7: 393–395.

    Article  CAS  Google Scholar 

  2. Pittenger M, Mackay A, Beck S, Jaiswal RK, Douglas R, Mosca JD et al. Multilineage potential of adult human mesenchymal stem cells. Science 2000; 284: 143–147.

    Article  Google Scholar 

  3. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002; 99: 3838–3843.

    Article  CAS  Google Scholar 

  4. Saccardi R, Mancardi GL, Solari A, Bosi A, Bruzzi P, Di Bartolomeo P et al. Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life. Blood 2005; 105: 2601–2607.

    Article  CAS  Google Scholar 

  5. Aggarwall S, Pittenger MF . Human mesenchymal cells modulate allogenic immune cell response. Blood 2000; 105: 1815–1822.

    Article  Google Scholar 

  6. Bacigalupo A, Valle M, Podesta' M, Pitto A, Zocchi E, De Flora A et al. T-cell suppression mediated by mesenchymal stem cells is deficient in patients with severe aplastic anemia. Exp Hematol 2005; 33: 819–827.

    Article  CAS  Google Scholar 

  7. Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringden O . HLA expression and immunological properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 2003; 31: 890–896.

    Article  CAS  Google Scholar 

  8. Campioni D, Moretti S, Ferrari L, Punturieri M, Castoldi GL, Lanza F . Immunophenotypic heterogeneity of bone marrow-derived mesenchymal stromal cells from patients with hematologic disorders: correlation with bone marrow microenvironment. Haematologica 2006; 91: 364–368.

    PubMed  Google Scholar 

  9. Drenou B, Le Friec G, Bernard M, Pangault C, Grosset JM, Lamy T et al. Major histocompatibility complex abnormalities in non-Hodgkin lymphoma. Br J Haematol 2002; 119: 417–424.

    Article  CAS  Google Scholar 

  10. Kimura H, Kimura M, Tzou SC, Chen YC, Suzuki K, Rose NR et al. Expression of class II major histocompatibility complex molecules on thyrocytes does not cause spontaneous thyroiditis but mildly increases its severity after immunization. Endocrinology 2005; 146: 1154–1162.

    Article  CAS  Google Scholar 

  11. Prockop SE, Palencia S, Ryan CM, Gordon K, Gray D, Petrie HT . Stromal cells provide the matrix for migration of early lymphoid progenitors through the thymic cortex. J Immunol 2002; 169: 4354–4361.

    Article  CAS  Google Scholar 

  12. Ruiz C, Reyes-Botella C, Garcia-martinez O, Montes MJ . Modulation of antigenic phenotype by IL-1b, INF-γ and TGF-β on cultured human decidual stromal cells. Biosci Rep 2004; 24: 55–62.

    Article  CAS  Google Scholar 

  13. Sotiropoulou PA, Perez SA, Salagianni M, Baxevanis CN, Papamichail M . Characterization of the optimal culture conditions for clinical scale production of human mesenchymal stem cells. Stem Cells 2006; 24: 1409–1410.

    Article  Google Scholar 

  14. Campioni D, Punturieri M, Bardi A, Moretti S, Tammiso E, Lanza F et al. ‘In vitro’ evaluation of bone marrow angiogenesis in myelodysplastic syndromes: a morphological and functional approach. Leuk Res 2004; 28: 9–17.

    Article  Google Scholar 

Download references

Acknowledgements

This work was supported by AIRC Regional Grant and MIUR (Italy).

Author information

Authors and Affiliations

  1. Section of Hematology, University Hospital, Ferrara, Italy

    F Lanza, D Campioni, S Moretti, L Ferrari & A Cuneo

  2. Section of Medical Genetics, University of Ferrara, Ferrara, Italy

    R Rizzo & R Baricordi

Authors
  1. F Lanza
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D Campioni
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Moretti
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L Ferrari
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R Rizzo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R Baricordi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A Cuneo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F Lanza.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lanza, F., Campioni, D., Moretti, S. et al. Aberrant expression of HLA-DR antigen by bone marrow-derived mesenchymal stromal cells from patients affected by acute lymphoproliferative disorders. Leukemia 21, 378–381 (2007). https://doi.org/10.1038/sj.leu.2404492

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404492

This article is cited by

Search

Advanced search

Quick links